Ningbo Xinwan Pharmaceutical Technology Co., Ltd.

This is a Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB004 Administered as Monotherapy or Combination Therapy in Subjects with Advanced Solid Tumors

This a A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, and Pharmacokinetics of NB003 in Subjects with Advanced Malignancies

主要目的： 评价RMX1002片多次口服给药治疗晚期实体瘤患者的安全性及耐受性，确定最大耐受剂量、II期推荐剂量及给药方案。 次要目的： 1.评价RMX1002片在晚期实体瘤患者体内的PK特征； 2.初步观察RMX1002片在晚期实体瘤患者中的初步疗效。 探索性目的： 初步探索药效动力学指标与疗效的潜在关系。